Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JAT
|
|||
| Former ID |
DIB014130
|
|||
| Drug Name |
PF-4427429
|
|||
| Synonyms |
PF-04427429; RI-307; Anti-CGRP antibodies (migraine), Pfizer
Click to Show/Hide
|
|||
| Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Phase 1 | [1] | |
| Company |
Labrys biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcitonin gene-related peptide (CALC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01117233) Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429. U.S. National Institutes of Health. | |||
| REF 2 | Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.